Aug 01,2024

Tempus Next Launches New Algorithm to Close Care Gaps in Guideline-Directed IHC Testing, Starting with HER2

Tempus has launched a new program within its Tempus Next platform, focused on using algorithms to identify patients likely to test positive for actionable biomarkers and require confirmatory testing per clinical guidelines. The program initially targets care gaps in human epidermal growth factor receptor 2 (HER2) testing for select metastatic cancers. The new RNA-based algorithm, part of the xR assay, predicts IHC/ISH positivity in tumor samples and notifies physicians about patients who might benefit from confirmatory HER2 testing. The program, now available at pilot sites, leverages Tempus' genomics, AI applications, and data analytics to provide real-time, guideline-directed care.

PRODUCT

#ai/software

View Analyst & Ambassador Comments
Go to original news
Mar 29,2023

Carevive releases a Spanish version of their remote patient monitoring workflow to reach more patients and reduce barriers to care

Carevive Systems has introduced a Spanish version of their remote symptom monitoring (RSM) workflow and PROmpt® app, aimed at enhancing cancer care for Spanish-speaking patients. This update addresses language barriers, which often lead to miscommunication and reduced care quality. By providing Spanish language support, Carevive aims to improve patient-clinician communication and health equity, benefiting the nearly 19% of Americans who are Hispanic or Latino.

PRODUCT

#rpm

View Analyst & Ambassador Comments
Go to original news
Mar 01,2023

Carevive Launches Native App Technology for the Carevive PROmpt® Patient Engagement Platform

Carevive Systems has launched a native app version of their PROmpt® platform, designed to enhance the monitoring and communication between cancer patients and their care teams. This new app, available on both Apple and Android devices, improves accessibility and usability, leading to better patient engagement and outcomes. The app facilitates symptom reporting from anywhere, enhances patient-care team communication, and integrates features like biometric authentication for easier logins.

PRODUCT

#mobile app

#rpm

View Analyst & Ambassador Comments
Go to original news
Jul 16,2024 TOP STORY

Thyme Care Closes $95M Series C To Fuel Cancer Care Affordability

Thyme Care, a value-based cancer care enabler, announced the close of a $95M capital raise. With $55M in equity funding, Thyme Care welcomes new investor Concord Health Partners with participation from all existing investors, including CVS Health Ventures, Town Hall Ventures, a16z Bio + Health, AlleyCorp, Echo Health Ventures, Frist Cressey Ventures, and Foresite Capital. Banc of California will provide an additional $40M in debt financing, bringing Thyme Care's total amount raised to date to $178M. Thyme Care's suite of services, including its 24/7 specialized cancer care navigation services, robust technology and data insights, and provider-led therapeutic interventions enable a more seamless patient experience and drive sustainability across the ecosystem.

FUNDING SERIES C
View Analyst & Ambassador Comments
Go to original news
Jul 10,2024

Researchers Customize AI Tools for Digital Pathology

Scientists from Weill Cornell Medicine and Dana-Farber Cancer Institute have developed AI tools for digital pathology, leveraging high-resolution digital images for disease diagnosis and treatment guidance. Their study, published in The Lancet Digital Health, shows that ChatGPT can be tailored for digital pathology and cancer biology to provide accurate responses and detailed results, aiding pathologists without coding expertise in using complex software. To address information glitches in general LLMs, Dr. Umeton started with a safe, private and secure ChatGPT version implemented at Dana-Farber Cancer Institute (GPT4DFCI). The researchers augmented GPT4DFCI with access to a comprehensive and curated database of the latest developments in digital pathology, consisting of 650 publications from 2022 onward, which added over 10,000 pages of literature.

CLINICAL STUDY

#ai/software

View Analyst & Ambassador Comments
Go to original news
Jul 02,2024

AI Model to Improve Patient Response to Cancer Therapy

Researchers at The Australian National University (ANU), in collaboration with the National Cancer Institute and Pangea Biomed, have developed an AI tool called DeepPT to improve cancer treatment selection. DeepPT predicts a patient's mRNA profile, crucial for personalized cancer medicine, and works alongside another tool, ENLIGHT, to forecast patient responses to various cancer therapies. Trained on data from over 5,500 patients across 16 cancer types, DeepPT improved patient response rates from 33.3% to 46.5%. It also utilizes histopathology images, which are readily available and cost-effective, reducing delays in processing molecular data. The study was published in Nature Cancer.

CLINICAL STUDY

#ai/software

#clinical decision support

View Analyst & Ambassador Comments
Go to original news
Jun 13,2024 TOP STORY

Veris Health Announces Launch of Pilot Program with The Ohio State University Comprehensive Cancer Center

PAVmed subsidiary Veris Health has initiated a pilot program in collaboration with The Ohio State University Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute. The program marks the first enrollment of patients on the Veris Cancer Care Platform, designed for personalized cancer care through remote patient monitoring using biologic sensors and connected devices. This platform integrates physiological data collection, symptom reporting, telehealth capabilities, and electronic health record integration. It aims to enhance cancer care by detecting complications early, reducing unplanned hospitalizations, providing longitudinal data trends, and offering data-driven risk management tools.

COLLABORATION PARTNERSHIP

#institution

#rpm

#connected device

View Analyst & Ambassador Comments
Go to original news
Jun 25,2024 TOP STORY

Guardian and Osara Health announce new cancer support partnership, expanding on Guardian's commitment to inspire well-being®

Guardian Life Insurance Company of America has partnered with Osara Health to offer its Cancer Coach program to members with long-term disability insurance who are diagnosed with cancer. This initiative integrates cancer support directly into Guardian's disability claim management, providing comprehensive assistance through a 12-week program. The program includes access to a dedicated health coach, personalized digital education modules, and the Osara Health app, focusing on mental health, nutrition, and overall wellness. With cancer diagnoses rising, Guardian aims to enhance support for affected members, promoting improved physical and mental health outcomes, faster return to work rates, and overall quality of life improvements.

COLLABORATION PARTNERSHIP

#insurance

#coaching

#mobile app

View Analyst & Ambassador Comments
Go to original news
Jun 02,2024

Tempus Introduces New HER2 & FOLR1 Testing Solutions to Support Personalized Patient Care

Tempus has introduced new testing solutions for identifying patients with HER2 or FOLR1 expressing tumors, potentially making them eligible for targeted therapies such as antibody–drug conjugates (ADCs). These tests, available for all solid tumor cancers, can be added to Tempus' xT or xR next-generation sequencing assays. ADCs are therapies that target and kill tumor cells while sparing healthy cells, making them highly effective for patients with specific indications like HER2 and FOLR1 expressing tumors. HER2 testing is essential for guiding targeted therapy decisions, and FOLR1 testing is recommended for patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer. Tempus' expanded testing portfolio aims to provide physicians with critical tools to optimize treatment options and improve patient outcomes.

PRODUCT

#ai/software

#clinical decision support

View Analyst & Ambassador Comments
Go to original news
Jun 01,2024

Massive Bio to Unveil Drug Utilization Optimizer (DUO) at ASCO Annual Meeting 2024

Massive Bio introduced its latest innovation, the Drug Utilization Optimizer (DUO), at the ASCO Annual Meeting 2024. DUO, an analytics and real-time notification platform, aims to transform how pharmaceutical commercial teams target and engage with physicians by providing advanced insights and efficiency. Leveraging the success of their SYNERGY-AI platform, DUO extends Massive Bio's capabilities into the commercial realm, offering real-time, granular insights for physician targeting and patient engagement.

PRODUCT

#ai/software

View Analyst & Ambassador Comments
Go to original news
Subscribe to ONCOLOGY